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Novel conjugated G-quadruplex-forming d(TG3AG) oligonucleotides, linked to hydrophobic groups
through phosphodiester bonds at 50-end, have been synthesized as potential anti-HIV aptamers, via a
fully automated, online phosphoramidite-based solid-phase strategy. Conjugated quadruplexes showed
pronounced anti-HIV activity with some preference for HIV-1, with inhibitory activity invariably in the
low micromolar range. The CD and DSC monitored thermal denaturation studies on the resulting quad-
ruplexes, indicated the insertion of lipophilic residue at the 50-end, conferring always improved stability
to the quadruplex complex (20 < DTm < 40 C). The data suggest no direct functional relationship
between the thermal stability and anti-HIV activity of the folded conjugated G-quartets. It would appear
that the nature of the residue at 50 end of the d(TG3AG) quadruplexes plays an important role in the ther-
modynamic stabilization but a minor inﬂuence on the anti-HIV activity. Moreover, a detailed CD and DSC
analyses indicate a monophasic behaviour for sequences I and V, while for ODNs (II–IV) clearly show that
these quadruplex structures deviate from simple two-state melting, supporting the hypothesis that inter-
mediate states along the dissociation pathway may exist.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
The chemical nature of nucleic acids provides a variety of spe-
ciﬁc and biologically relevant interactions with different classes
of biomolecules.1–4 Aptamers are DNA sequences that can bind
selectively and speciﬁcally to target molecules. Their small size,
straightforward synthesis, and ﬂexibility make aptamers advanta-
geous over other molecules, such as antibodies. The structure and
conformation of aptamers can be rationally designed and tailor-
made for various types of targets.
Recently, the use of synthetic nucleic acids to modulate the
activities of proteins for therapeutic purposes has received major
attention. In this ﬁeld, G-rich oligonucleotides (GROs), which are
able to form G-quadruplexes, have attracted considerable inter-
est.5–8 GROs are among the most studied DNA structures because
they are thought to be involved in important biological processes
such as the modulation of gene expression resulting by protein rec-
ognition of G-quadruplex structures. They also show promisingbiological properties ranging from anticancer to antiviral activities.
In all cases, G-quadruplex formation is a crucial prerequisite for
these biological effects.9,10
Many G-quadruplex forming oligonucleotides have been found
to be potent antiviral agents, and a number of these agents has
been modiﬁed and selected as promising drug candidates against
HIV (human immunodeﬁciency virus).11–15 Two mechanisms have
been proposed to explain the antiviral activity of G-rich oligomers:
the inhibition of viral entry into the cell via interaction with the
positively charged V3 loop of the gp120 envelope protein (primary
target), and/or the inhibition of the HIV-1-encoded integrase (sec-
ondary target). The ﬁrst G-quadruplex forming oligonucleotide to
exhibit potent anti-HIV activity was the 8-mer d(T2G4T2), which
was shown to bind to the V3 loop of the envelope protein gp120
and inhibit virus adsorption and cell fusion.16 Recently, several
short G-quadruplexes have been evaluated as potential anti-HIV
drug candidates, due to their binding with proteins related for
the HIV-1 infection. The intramolecular or intermolecular quadru-
plex structural motifs were thought to be essential to anti-HIV
activity.12,13,17–25
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conjugated to a variety of aromatic groups at the 50-end and tested
for activity against HIV-1.26–28 While the unmodiﬁed quadruplex
d(TG3AG) had no anti-HIV-1 activity, quadruplexes carrying aro-
matic groups at the 50-end inhibited HIV-1 with low cytotoxicity.
In particular, the d(TG3AG) quadruplex forming ODNs bearing a
3,4-dibenzyloxybenzyl group at the 50-ends and 2-hydroxyethyl-
phosphate at the 30-ends (R-95288) showed the highest anti-HIV
activity. Spectroscopic studies suggested that 50-conjugated d(TG3-
AG) formed parallel tetramolecular quadruplex structures. The
synthesis and the structure–activity relationship of novel modiﬁedO
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aFor HPLC conditions see paragraph 4.3.Hotoda’s sequences29–32 have become the focus of many studies
because of their pharmaceutical potential.
To explore the relationship between the structure of these
G-rich ODNs and their activity, we analysed some representative
anti-HIV Hotoda’s 6-mers and compared them with unmodiﬁed
d(TG3AG).33,34 Based on previous studies, we hypothesised that
the aromatic groups at the 50-end are crucial for the stability of
the G-quadruplex, dramatically enhancing both the rate of forma-
tion and the thermodynamic stability of the quadruplex complexes
and therefore their anti-HIV activity. Recently, we described a gen-
eral approach to generating a mini library of new d(TG3AG) ODNs,N
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Figure 2. CD spectra of I–V. The spectra were collected at 15 C and at steps of 5 C
up to 90 C in a 10 mM potassium phosphate buffer (pH 7.0), supplemented with
200 mM KCl, at 10 lM of single strand. To guide the eye throughout the ﬁgures,
some representative curves are marked with the temperature at which the CD
signal was recorded.
Table 2
Thermodynamic parameters for the thermally-induced Quadruplex dissociationa
CD DSC
Tm (C) ± 1 Tm (C) ± 1 DHcal (KJmol1)
1st 2nd 1st 2nd 1st 2nd
I nd 56 nd 61 nd 314 ± 15
II 46 71 46 74 nd 305 ± 10
III 33 79 33 90 15 ± 5 124 ± 11
IV 45 79 45 81 24 ± 15 252 ± 15
V nd 76 nd 84 nd 182 ± 10
a The same sample was splitted in two parts used in parallel for CD and DSC
analysis.
962 V. Romanucci et al. / Bioorg. Med. Chem. 22 (2014) 960–966conjugated to different aromatic groups at the 50-end through a
phosphodiester bond.35 Several modiﬁed sequences showed signif-
icant anti-HIV-1 activity and high binding afﬁnity for the HIV-1
envelope proteins gp120 and gp41. CD analyses showed that the
residues at the 50-end in these structures played a principal role
on the G-quadruplex stability by enhancing thermodynamic stabil-
ity (DTm >20 C).
Given the importance of G-tetraplex forming ODNs as potent
anti-HIV inhibitors, we aimed to conjugate suitable molecules able
to stabilise quadruplexes through aromatic and non-aromatic
interactions. To extend the number of modiﬁed G-rich ODNs and
to perform a detailed study of the structure–activity relationship,
we synthesised and biophysically and biologically characterised a
mini-library of new d(TG3AG) oligomers I–V carrying hydrophobic
and groups at the 50-end by a phosphodiester bond. Some of the
groups are known for their ability to improve cellular uptake, ex-
tend the half-life of these molecules in plasma, or stabilise DNA
structures through hydrophobic interactions.36–39
Detailed CD analysis and thermal denaturation DSC/CD studies
for the 50-conjugated d(TG3AG) I–Vwere carried out and discussed.
To examine the structure–activity relationship, ODNs I–V were
evaluated for their anti-HIV activity and their afﬁnity for HIV enve-
lope proteins gp120, gp41 and human serum albumin (HSA).
2. Results and discussion
Based on Hotoda’s sequence, d(TG3AG), a small library of
50-conjugates carrying aromatic, hydrophobic, amphiphilic, ﬂuo-
rescent groups was synthesised and puriﬁed. Initially, the scaffold
6 (Fig. 1) was synthesised using standard solid phase b-cyanoethyl
phosphoramidite chemistry protocols starting from a commer-
cially available DMT-protected guanosine functionalised CPG
support.40 Phosphoramidite derivatives 1–5 (Fig. 1) were exploited
in the last coupling step to synthesise the 50-conjugated oligomers
I–V (Fig. 1 and Table 1).
CD spectroscopy can be used to obtain details about the quad-
ruplex structures by comparing their spectra with those of quadru-
plex DNAs with known conformations.41 Figure 2 shows the CD
spectra of the ﬁve oligonucleotides at temperatures ranging from
15 to 90 C in the same buffer conditions.
The CD spectra of all ﬁve sequences recorded at 15 C show a
positive peak at 260 nm and a small negative band around 240 nm.
These spectral shapes are consistent with the reported spectra
of other TG3AG sequences33 and clearly indicate that all of the
strands fold into an all-parallel-stranded structure. The melting
temperature values (Table 2) were determined from the CD melt-
ing proﬁles for conjugates I–V monitored at 263 nm with an heat-
ing rate of 1 C/min, (Fig. 3, bottom). In Figure 3 (top), the DSC
results from the same samples used in the CD melting experiments
are presented.
A direct comparison of the CD and DSC data obtained for iden-
tical samples can be used to rule out the possibility of incompletely
formed quadruplexes before heating and provide a more detailed
description of the thermal transitions. All heating runs were fully
irreversible. Therefore, neither an extrapolation of the thermody-
namic parametersDG andDS from the melting curves nor a decon-
volution of the Cp curves by statistical mechanic methods were
possible.38 For compound I, DSC runs exhibited a broad monopha-
sic peak centred at Tm = 60 C andDHcal = 314 kJ mol1, which indi-
cates the formation of four G-tetrads, as reported elsewhere.30 The
melting temperature of compound I derived from the DSC curves
was 4 C higher than that obtained from the CD results. This differ-
ence in the melting temperatures may be ascribed to the asymme-
try of the calorimetric trace. The CD melting curve of compound II
shows biphasic behaviour with a ﬁrst melting point centred at
46 C and a second one observed at 71 C. The corresponding DSCcurve shows a large asymmetric peak with a maximum at 73 C
and a small shoulder at 46 C. The overall calorimetric enthalpy
of this peak is 305 kJ mol1. Biphasic behaviour is observed in
the CD melting curve of compound III; the ﬁrst transition is ob-
served at 33 C, and the second transition is observed at 79 C.
The DSC curve of compound III shows an endothermic peak at
33 C corresponding to the CD transition and a second, distinct
peak at 89 C. The calorimetric enthalpies for these two transitions
are 15 and 124 kJ mol1, respectively. The CD melting proﬁle of
compound IV exhibits biphasic behaviour, with the ﬁrst transition
at 45 C and a second transition at 79 C.
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Figure 3. DSC (top) and CD (bottom) melting proﬁles of I–V.
Table 3
Antiviral (HIV) and RT activities of test compounds in CEM cell cultures
Sequences EC50a (lM) IC50b (lM)
HIV-1(IIIB) HIV-2(ROD) RT (Pol.rC.dG)
I >8 68 ± 18 n.d.
II 9.9 ± 4.4 31 ± 0.0 >30
III 4.8 ± 0.3 6.6 ± 1.9 2.5 ± 0.63
IV 6.8 ± 1.8 12 ± 9.7 >30
V 5.3 ± 0.2 P8 6.72 ± 0.48
a 50% Effective concentration or compound concentration required to inhibit
HIV-induced cytopathicity by 50% in CEM cell cultures.
b 50% inhibitory concentration required to inhibit the RT reaction by 50%.
Table 4
Interaction of the quadruplex derivatives with viral and human (glyco)proteins
Sequences Amplitude of the SPR signala (RU)
HIV-1 gp120 HIV-1 gp41 HSAb
II 0.4 4.0 13
III 8.7 28 45
IV 4.7 35 6.0
V 0.1 21 21
a Amplitude of the SPR signal was measured after 120 s exposure of the com-
pounds to the (glyco)proteins.
b Human Serum Albumin.
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45 C and a second peak at 81 C. The calorimetric enthalpies for
the two transitions are 24 and 252 kJ mol1, respectively. Finally,
the CD melting proﬁle of compound V shows a single transition
at 76 C. The DSC curve of compound V shows monophasic behav-
iour, with an endothermic peak centred at 84 C with a calorimet-
ric enthalpy of 188 kJ mol1. Several research groups have reported
that modiﬁed G-quadruplex d(TG3AG) sequences are stabilised at
increasing melting temperatures relative to the parent unmodiﬁedsequence. Our results (Table 2) are consistent with these reports;
however, we found that the melting of many of these structures
is not a simple two-state process, as assumed in previous studies.
Although the irreversible nature of the melting processes of the
studied assemblies made a thorough analysis of the <DCp> curves
in thermodynamic terms difﬁcult, our integrated CD and DSC dis-
sociation studies provide a better understanding of the complexi-
ties in the melting mechanism. The CD melting data for
compounds II, III and IV clearly show that these quadruplex struc-
tures deviate from a simple two-state melting and support the
hypothesis that intermediate states along the dissociation pathway
may exist. Such complex behaviour is consistent with the analysis
of the DSC thermograms. However, the existence of intermediates
along the broad melting curve of compound I cannot be excluded.
It should be noted that the folding/unfolding reactions of G-Quad-
ruplexes are almost always assumed for convenience to be two-
state processes, with negligible concentrations of any intermediate
species along the melting pathway. However, a number of studies
have revealed that in both Na+ and K+ solutions, multiple confor-
mations may coexist.42–45 A thermally dependent equilibrium be-
tween two G-quadruplex isoforms with different stabilities
would explain the biphasic melting curves observed. Lower ther-
mal stability is generally attributed to ﬂanking interstrand contacts
at the edges of the G-Quadruplex structures.
Compounds I–V were evaluated for their anti-HIV-1 and -HIV-2
activities in CEM cell cultures (Table 3). All compounds showed
pronounced anti-HIV activities, with some preference for HIV-1.
This inhibitory activity (except compound I) was invariably in
the low micromolar range (50% effective concentration (EC50:
4.9–10 lM for HIV-1 and 6.7–32 lM for HIV-2). Compound I was
clearly less inhibitory (EC50 >8 lM for HIV-1 and 69 lM for HIV-
2). A concentration higher than 8 lM could not be microscopically
scored due to unexplained toxicity in the HIV-1-infected (but not
HIV-2-infected) CEM cell cultures. In light of the thermodynamic
data and biological activity, it is reasonable to conclude that the
nature of the 50-end modiﬁcation on the d(TG3AG) quadruplexes
 For detail see Supporting Information (S.I.) ﬁle.
964 V. Romanucci et al. / Bioorg. Med. Chem. 22 (2014) 960–966played only a minor role in the anti-HIV activity. Because the con-
jugated quadruplexes may inhibit HIV entry into its target cells due
to their negative charge, conjugates II–V were also evaluated for
their afﬁnity to HIV envelope gp120 and gp41, as well as HSA as
a control, by surface plasmon resonance (SPR) technology (Table 4)
and for their inhibitory effect against HIV-1 reverse transcriptase
(RT). The biosensor chips for the SPR analyses were loaded with
3531 RU gp120, 3091 RU gp41, or 3333 RU HSA and exposed to
1 OD/ml of the compounds. A binding signal was recorded for each
of the compounds against the three proteins.
However, the binding amplitudes measured after compound
exposure to the protein for 120 s differed signiﬁcantly depending
on the nature of the compound and the glycoprotein evaluated.
The compounds III and IV showed a clear binding capacity (ampli-
tude range: 4.7–8.7 RU) to gp120 whereas II and V showed poor, if
any binding. Compounds III, IV and Vwere by far superior for bind-
ing to gp41, and compound III showed the strongest binding to
HSA (Table 4 and Supporting Informations).
Compounds III and V bound to HSA better than to gp41. In the
HIV-1 RT experiments, II, III, IV and V showed varying inhibitory
activities (I was not evaluated). Their IC50 values were in the range
2.5–69 lM, respectively, when using poly rC.dG as the template/
primer and radiolabeled [3H]dGTP as the substrate (Table 3).
Considering all of the SPR data, there does not appear to be any
selectivity for gp120 or gp 41 binding compared with HSA binding.
Also, no correlation between anti-HIV-1 and anti-RT activity was
found. Therefore, it remains unclear whether selective binding to
the HIV envelope or RT inhibition represents a mechanism for
the selective antiviral action of these conjugates.
The afﬁnity of the synthetic oligonucleotides (II–V) for HSA is
an interesting ﬁnding because the use of albumin as a versatile
drug carrier in anti-HIV strategy is increasing. In fact, many albu-
min-based formulations have received market approval or are
being evaluated in clinical trials.46,47 In light of these results, it
would be interesting to investigate the ability of all active 50-end
conjugated d(TG3AG) to bind HSA.
3. Conclusions
In conclusion, new d(TG3AG) ODNs carrying aromatic, hydro-
phobic, amphiphilic and ﬂuorescent tails at the 50-end via a phos-
phodiester bond were synthesized as potential anti-HIV agents via
a fully automated, on-line phosphoramidite-based solid-phase
method. The compounds I–V showed enhanced anti-HIV activity
with some selectivity for HIV-1. The new compounds have also
been evaluated for their afﬁnity to the HIV envelope glycoproteins
gp120 and gp41 and human serum albumin by SPR and for their
inhibition of HIV-1-encoded reverse transcriptase. The compounds
III and V showed almost equal binding capacity to gp120 whereas
compounds III, IV and V were superior to II for binding to gp41,
and compound III showed strongest binding to HSA. Moreover,
compound III bound to HSA better than to gp41. DSC and CD anal-
yses were carried out for the conjugates I–V and revealed diagnos-
tic proﬁles of parallel-stranded quadruplex structures for all of the
sequences studied. While the CD and DSC analyses for sequences I
and V indicated monophasic behavior with an endothermic peak,
the results for compounds II–IV clearly showed that these quadru-
plex structures deviate from a simple two-state melting and sup-
port the hypothesis that intermediate states along the
dissociation pathway may exist. As already reported, we can con-
clude that the formation of quadruplex structures for modiﬁed
G-rich oligonucleotides appears to be necessary for their antiviral
activity. An in-depth analysis is required to understand the role
of conjugating molecules. Structural characterization studies com-
bining kinetic analysis with molecular modeling of the ODNs pre-
sented here and in previous work35 are currently underway in ourlaboratories to obtain a more complete picture of their structure–
activity relationships, which will be useful for the design of new
conjugated G-quadruplexes as aptamers.
4. Exprimental procedures
4.1. General procedures
Starting compounds for the synthesis of phosphoramidites 1–5
were all purchased from Sigma–Aldrich. TLC analyses were carried
out on silica gel plates from Merck (Kieselgel 60, F254). Reaction
products were visualized on TLC plates by UV light and then by
treatment with a H2SO4/AcOH aqueous solution. For column chro-
matography, silica gel from Merck (Kieselgel 40, 0.063–0.200 mm)
was used. NMR spectra were recorded in CDCl3 with a Bruker WM
400 spectrometer. The chemical shifts (d) are given in ppmwith re-
spect to the residual solvent signal (7.26 ppm), and the coupling
constants (J) are in Hz. 31P NMR spectra were recorded at
161.98 MHz on a Bruker WM-400 spectrometer using 85% H3PO4
as an external standard. MALDI TOF mass spectrometric analyses
were performed on a PerSeptive Biosystems Voyager—De Pro MAL-
DI mass spectrometer in the linear mode using a picolinic/3–
hydroxypicolinic/sinapinic acid mixture as the matrix. For the ESI
MS analyses, a Waters Micromass ZQ instrument equipped with
an Electrospray source was used in the positive mode. HPLC anal-
yses were performed on an Agilent Technologies 1200 series
instrument equipped with a UV detector. The crude material was
analysed and puriﬁed by HPLC on a Nucleogel SAX column (Mache-
rey–Nagel, 1000–8/46) or Phenomenex RP18 column [LUNA, 5 lm
C18(2), 10.0  250 mm]. Desalting was carried out by gel ﬁltration
chromatography on a Sephadex G25 column eluted with H2O/EtOH
4:1 (v/v).
4.2. General procedure for the Preparation of Phosphoramidite
1–5
1.26 mmol of alcohol was dissolved in 10 mL of anhydrous
dichloromethane, and 880 lL DIPEA (5.05 mmol) and 565 lL
2-cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite (2.52
mmol) were added under argon. After 30 min, the solution was
diluted with ethyl acetate, and the organic phase was washed
twice with brine and then concentrated. Silica gel chromatography
of the residue (eluent hexane/ethyl acetate) afforded the desired
compounds (1–5).
1 1H NMR (CDCl3, 400 MHz, 20 C, mixture of enantiomers): d
7.58 (3H, overlapped signals, H-4, H-8 and H-5), 7.15 (2H, over-
lapped signals, H-7 and H-9), 7.17 (1H, m, H-1), 7.04 (1H, d,
J = 8.5 Hz, H-3), 3.73 (2H, m, OCH2CH2CN), 3.56 (2H, m,
N[CH(CH3)2]2), 2.46 (2H, t, J = 8.0 Hz, OCH2CH2CN), 1.04 (6H, d,
J = 8.0 Hz, N[CH(CH3)2]2), 0.98 (6H, d, J = 8.0 Hz, N[CH(CH3)2]2);
13C NMR (CDCl3, 75 MHz): d. 151.8, 134.0, 129.5, 129.1, 127.4,
126.8, 126.0, 124.0, 121.1, 117.4, 114.7, 58.7, 43.4, 24.2, 24.0,
20.3, 19.9. 31P NMR (CDCl3, 161.98 MHz): d 149.2. ESI–MS: calcu-
lated for C20H26NO2P 343.17. Found (positive ions): 344.26
(MH)+.
2 1H NMR (CDCl3, 400 MHz, 20 C, mixture of enantiomers): d
8.53 (1H, d, J = 8.4 Hz), 8.30 (1H, d, J = 8.4 Hz), 8.24 (1H, d,
J = 7.2 Hz), 7.53 (2H, m), 7.18 (1H, d, J = 7.6 Hz), 3.75–3.44 (6H,
overlapped signals, OCH2CH2CN, NHCH2CH2O and N[CH(CH3)2]2),
3.08 (2H, m, NHCH2CH2O), 2.86 (6H, s, NCH3), 2.55 (2H, m, OCH2-
CH2CN), 1.25 (6H, d, J = 6.6 Hz, N[CH(CH3)2]2), 1.04 (6H, d,
J = 6.7 Hz, N[CH(CH3)2]2). 13C NMR (CDCl3, 75 MHz): d 151.9,
130.3, 129.7, 129.4, 128.3, 123.1, 119.6, 118.6, 117.6, 115.1, 62.2,
V. Romanucci et al. / Bioorg. Med. Chem. 22 (2014) 960–966 96558.3, 45.3, 44.1, 42.9, 24.4, 20.1. 31P NMR (CDCl3, 161.98 MHz): d
151.7. ESI–MS: calculated for C34H61N2O5P 608.43. Found (positive
ions): 609.51 (MH)+.
3 1H NMR (CDCl3, 400 MHz, 20 C, mixture of diastereoiso-
mers): d 8.23 (2H, d, J = 7.6 Hz), 7.63 (1H, t, J = 7.6 Hz), 7.51 (2H,
t, J = 7.6 Hz), 7.33 (1H, dd, J = 8.4, 3.2 Hz), 6.97 (1H, d, J = 8.4 Hz),
6.93 (1H, s), 3.80–3.76 (3H, complex signal, OCH2CH2CN, H-17 of
b–estradiol residue), 3.64–3.58 (2H, complex signal, N[CH(CH3)2]2).
13C NMR (75 MHz, CDCl3): d 165.4, 148.6, 138.3, 138.1, 133.4,
130.1, 129.6, 128.5, 126.4, 121.6, 118.6, 117.8, 83.7, 82.5, 58.4,
57.8, 49.7, 44.1, 43.5, 42.9, 38.4, 37.2, 36.9, 29.6, 26.9, 26.1, 24.6,
23.2, 20.4, 11.9, 11.7. 31P NMR (161.98 MHz, CDCl3): d 150.5,
149.5. 31P NMR (CDCl3, 161.98 MHz): d 150.5, 149.5. ESI–MS: cal-
culated for C27H41N2O3P 473.29. Found (positive ions): 474.69
(MH)+.
4 1H NMR (CDCl3, 400 MHz, 20 C, mixture of diastereoiso-
mers): d 5.02 (1H, br s), 4.90 (1H, br s), 4.58 (1H, m), 4.09 (2H, t,
J = 5.0 Hz), 3.80 (2H, complex signals), 3.58 (4H, complex signals),
2.63 (2H, t, J = 6.3 Hz), 2.13 (3H, s), 2.08 (3H, s), 2.05 (3H, s),
1.95–0.65 (45H, complex signals). 13C NMR (CDCl3, 75 MHz): d
169.0, 169.1, 168.7, 74.2, 73.0, 69.2, 63.8, 60.2, 48.5, 47.6, 43.3,
43.1, 42.3, 41.2, 40.6, 37.2, 36.6, 36.0, 33.4, 31.3, 30.8, 30.5, 29.7,
28.9, 28.0, 25.4, 24.4, 23.3, 23.0, 20.02, 18.2, 13.1. 31P NMR (CDCl3,
161.98 MHz): d 151.7, 150.7. ESI–MS: calculated for C33H59N2O5P
594.42 Found (positive ions): 595.32 (MH)+.
5 1H NMR (CDCl3, 400 MHz, 20 C, mixture of enantiomers): d
3.80 (2H, m, OCH2CH2CN,), 3.58 (4H, complex signals,
N[CH(CH3)2]2, OCH2CH2(CH2)9CH3), 2.63 (2H, t, J = 6.3 Hz, OCH2-
CH2CN), 1.56 (2H, m, OCH2CH2(CH2)9CH3), 1.34–1.12 (30H, m,
N[CH(CH3)2]2, OCH2CH2(CH2)9CH3, 0.87 (3H, t, J = 6.0 Hz). 13C
NMR (CDCl3, 75 MHz): d 119.4, 63.7, 58.3, 42.9, 31.9, 31.2, 29.8,
29.6, 29.5, 26.1, 24.5, 22.6, 20.3, 14.0. 31P NMR (CDCl3,
161.98 MHz): d 152.9. ESI–MS: calculated for C21H43N2O2P
386.31. Found (positive ions): 387.55 (MH)+.
4.3. Synthesis and Characterisation of ODNs (I–V)
As depicted in Figure 1, oligomers I–V were synthesised, start-
ing from functionalised CPG support 6with 0.07–0.08 meq/g initial
loading, on which the sequence d(TG3GAG) was assembled in a
standard manner. Starting with 100 mg of commercially available
CPG-dG support with 0.10 meq/g initial loading, and after the
assembly of the sequence d(TGGGA), an additional coupling with
phosphoramidite building blocks 1–5 was then performed. Target
oligomers I–V were detached from the solid support and deprotec-
ted by treatment with Et3N/pyridine (1:1, v/v) at 50 C for 1 h, fol-
lowed by treatment with conc. aq. ammonia at 50 C for 5 h. The
combined ﬁltrates and washings were concentrated under reduced
pressure, re-dissolved in H2O, and analysed and puriﬁed by HPLC.
Puriﬁcation of the crude conjugated oligonucleotides I–V was car-
ried out on Phenomenex RP18 column or RP18 column (LUNA,
5 lm C18(2), 10.0  250 mm) using a linear gradient of CH3CN in
0.1 M AcNH4 in H2O, pH 7.0 from 5% to 100% over 30 min at a ﬂow
rate of 1.5 mL/min with detection at 260 nm. In all cases 50–80 OD
units of pure I–V could be on average recovered starting from
100 mg of functionalized solid support (average yields 16–25%).
4.4. Quadruplexes preparation
The quadruplex complexes were obtained by dissolving the
lyophilized oligonucleotide at a single strand concentration of
1  104 M in the appropriate buffer. The solution was then an-
nealed by heating at 90 C for 5 min and slow cooling to room tem-
perature. The buffer used was 10 mM potassium phosphate,
200 mM KCl, 0.1 mM EDTA at pH 7.0. The concentration of the dis-
solved oligonucleotides I–V was determined by UV measurementsat 260 nm and at 95 C, using, as the molar extinction coefﬁcients,
the values calculated by the nearest neighbor model for the se-
quence d(TG3AG), and the values experimentally calculated for la-
bels 1–3 (808, 1083, and 703 cm1 M1, respectively).
4.5. CD experiments
CD spectra were recorded by a JASCO J-810 spectropolarimeter
equipped with a thermostatically controlled accessory (JASCO PTC-
348), using a quartz cuvette with a 0.5 cm optical path. CD spectra
were collected from 220 to 340 nm, at 20 nm/min, with a response
time of 4 s and at 1 nm bandwidth. The CD signal of the buffer was
subtracted from all CD spectra, corresponding to an average of 5
scans. The molar ellipticity was calculated by the equation
[h] = 100  h/cl where h is the ellipticity value, c is the concentra-
tion of the single strand (1.0  105 M), and l is the path length
of the cell in cm. The thermally-induced dissociation of the quad-
ruplexes was studied by monitoring the CD signal at 263 nm upon
increasing the temperature from 15 to 90 C (heating rate = 1 C/
min). The melting temperatures were calculated from the peaks
of the ﬁrst derivative of the CD signal vs T.
4.6. DSC experiments
DSC runswere all performedby aVP-DSC calorimeter (MicroCal).
All samples, after a degassingprocess,were scannedat a heating rate
of 1 C min1 in the temperature range20–120 C in the sameexper-
imental conditions adopted for the CD experiments. An extra exter-
nal pressure of about 29 psi was applied to the solution to prevent
the formation of air bubbles during heating. To ensure a complete
equilibration of the calorimeter, several buffer–buffer heating scans
were routinely performed prior to the measurement. Only after
obtaining invariant buffer–buffer baselines samples were scanned.
Additional buffer–buffer baselineswere obtained immediately after
the protein scans to double-check for uncontrolled drifts in instru-
mental baseline. For each sample, three independent DSC experi-
ments were carried out under the same buffer conditions. To
obtain the heat capacity Cp curves, buffer–buffer base lines were re-
corded at the same scanning rate and then subtracted from sample
curves, as previously described.48 In all experiments, one or several
heating–cooling cycleswere carried out to determine the reversibil-
ity of the denaturation process. To obtain the excess heat capacity
proﬁles <DCp>, the DSC curves, after instrumental baseline correc-
tion,were subtracted fromabaselineobtainedbya third-orderpoly-
nomial ﬁt of the pre- and post-transition Cp trends as reported
elsewhere.49–51 Melting temperatures were calculated from the
maximum Cp value of the DSC curve.
4.7. Anti-HIV experiments
Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced cytopathicity
in CEM cell cultures was measured in microliter 96-well plates
containing 3  105 CEM cells/mL infected with 100 CCID50 of
HIV per milliliter and containing appropriate dilutions of the test
compounds. After 4–5 days of incubation at 37 C in a CO2-
controlled humidiﬁed atmosphere, CEM giant (syncytium) cell
formation was examined microscopically. The EC50 (50% effective
concentration) was deﬁned as the compound concentration
required to inhibit HIV-induced giant cell formation by 50%.
4.8. Surface plasmon resonance (SPR) analysis
Interaction studies were performed on a Biacore T200 instru-
ment (GE Healthcare, Uppsala, Sweden) at 25 C in HBS-P
(10 mM HEPES, 150 mM NaCl and 0.05% surfactant P20; pH 7.4)
supplemented with 10 mM CaCl2. Recombinant HIV-1(IIIB) gp120
966 V. Romanucci et al. / Bioorg. Med. Chem. 22 (2014) 960–966(ImmunoDiagnostics Inc., Woburn, MA), recombinant HIV-1(HxB2)
gp41 (Acris Antibodies GmbH, Herford, Germany) and human ser-
um albumin (HSA) (Sigma) were covalently immobilized on a CM5
sensor chip in 10 mM sodium acetate, pH 4, using standard amine
coupling chemistry, resulting in chip densities of respectively
3531, 3091 and 3333 RU. A reference ﬂow cell was used as a con-
trol for non-speciﬁc binding and refractive index changes. Samples
were injected for 2 min at a ﬂow rate of 45 ll/min and followed by
a dissociation phase of 2 min. The CM5 sensor chip surface was
regenerated with a single injection of Glycine–HCl pH = 3.
4.9. HIV-1 reverse transcriptase assay
Enzyme reactions (50 lL in volume) were carried out in a
50 mM Tris–HCl (pH 7.8) buffer that contained 5 mM dithiothrei-
tol, 300 mM glutathione, 0.5 mM EDTA, 150 mM KCl, 5 mM MgCl2,
1.25 lg of bovine serum albumin, 0.06% Triton X-100, an appropri-
ate concentration of 2.8 lM [3H]dGTP (2 lCi/assay), varying con-
centrations of the test compounds, and a ﬁxed concentration of
poly(rC)/oligo(dG) (0.1 mM). Reactions were initiated by the addi-
tion of 1 lL of wild-type or mutant RT and were incubated for
30 min at 37 C. Reactions were terminated by the addition of
200 lL of 2 mg/mL yeast RNA, 2 mL of 0.1 M Na4P2O7 (in 1 M
HCl), and 2 mL of 10% (v/v) trichloroacetic acid. The solutions were
kept on ice for 30 min, after which the acid-insoluble material was
washed and analyzed for radioactivity.
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